N
Natasha Purington
Researcher at Stanford University
Publications - 57
Citations - 1103
Natasha Purington is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 40 publications receiving 535 citations.
Papers
More filters
Journal ArticleDOI
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study
R. Sharon Chinthrajah,Natasha Purington,Sandra Andorf,Andrew Long,Katherine O'Laughlin,Shu Chen Lyu,Monali Manohar,Scott D. Boyd,Robert Tibshirani,Holden T. Maecker,Marshall Plaut,Kaori Mukai,Mindy Tsai,Manisha Desai,Stephen J. Galli,Kari C. Nadeau +15 more
TL;DR: It is suggested that peanut OIT could desensitise individuals with peanut allergy to 4000 mg peanut protein but discontinuation, or even reduction to 300 mg daily, could increase the likelihood of regaining clinical reactivity to peanut.
Journal ArticleDOI
Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial
Sandra Andorf,Natasha Purington,Whitney Block,Andrew Long,Dana Tupa,Erica Brittain,Amanda Rudman Spergel,Manisha Desai,Stephen J. Galli,Kari C. Nadeau,R. Sharon Chinthrajah +10 more
TL;DR: In multifood allergic patients, omalizumab improves the efficacy of multifood OIT and enables safe and rapid desensitization.
Journal ArticleDOI
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.
Prasanna Jagannathan,Jason R. Andrews,Hector Bonilla,Haley Hedlin,Karen B. Jacobson,Vidhya Balasubramanian,Natasha Purington,Savita Kamble,Christiaan R. de Vries,Orlando Quintero,Kent Y Feng,Catherine Ley,Dean L. Winslow,Jennifer A Newberry,Karlie Edwards,Colin Hislop,Ingrid Choong,Yvonne Maldonado,Jeffrey S. Glenn,Ami S. Bhatt,Catherine A. Blish,Taia Wang,Chaitan Khosla,Benjamin A. Pinsky,Manisha Desai,Julie Parsonnet,Upinder Singh +26 more
TL;DR: In this article, the authors conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding or symptoms.
Journal ArticleDOI
A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
Sandra Andorf,Natasha Purington,Divya Kumar,Andrew Long,Katherine O'Laughlin,Scott H. Sicherer,Hugh A. Sampson,Antonella Cianferoni,Terri Brown Whitehorn,Daniel Petroni,Melanie M. Makhija,Rachel G. Robison,Michelle B. Lierl,Stephanie L. Logsdon,Manisha Desai,Stephen J. Galli,Efren L. Rael,Amal Assa'ad,Sharon Chinthrajah,Jacqueline A. Pongracic,Jonathan M. Spergel,Jonathan S. Tam,Stephen A. Tilles,Julie Wang,Kari C. Nadeau +24 more
TL;DR: These results suggest that sustained desensitization after omalizumab-facilitated multi-OIT best occurs through continued maintenance OIT dosing of either 300 mg or 1 g of each food allergen as opposed to discontinuation of multi- OIT.
Journal ArticleDOI
Development of a tool predicting severity of allergic reaction during peanut challenge
R. Sharon Chinthrajah,Natasha Purington,Sandra Andorf,Jaime S. Rosa,Kaori Mukai,Robert G. Hamilton,Bridget Smith,Bridget Smith,Ruchi Gupta,Ruchi Gupta,Stephen J. Galli,Manisha Desai,Kari C. Nadeau +12 more
TL;DR: The CSS is a novel tool that combines dose thresholds and allergic reactions to understand risks associated with peanut OFCs and Laboratory values (CD63 ratio), along with clinical variables (exercise-induced asthma and FEV1/FVC ratio) contribute to the predictive ability of the severity of reaction to peanut OfCs.